CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

OtherAdvancedMedium Risk

Adamantylglycine

Also known as: AdaGly

Adamantylglycine is an NMDA receptor modulator structurally related to the adamantane class of compounds (which includes memantine). It is researched for potential neuroprotective and cognitive-enhancing properties.

Evidence10/100 — Minimal

Risk Level

Medium Risk

Difficulty

Advanced
Molecular FormulaC12H19NO3
ClassOther
CategoryOther Performance Compounds

Mechanism of Action

Adamantylglycine modulates NMDA receptor activity at the glycine binding site. By fine-tuning glutamatergic neurotransmission, it may protect against excitotoxicity while maintaining normal synaptic plasticity. The adamantane moiety provides blood-brain barrier penetration.

Dosing Research

No established human dosing. Extremely limited research. Experimental compound with no clinical protocols. Available only as a research chemical.

Side Effects & Risks

Virtually unknown. NMDA modulation carries theoretical risks of cognitive disruption. No human safety data available. Should be considered a high-uncertainty research chemical.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ